169 related articles for article (PubMed ID: 15890515)
1. 4,5-Disubstituted cis-pyrrolidinones as inhibitors of type II 17beta-hydroxysteroid dehydrogenase. Part 2. SAR.
Gunn D; Akuche C; Baryza J; Blue ML; Brennan C; Campbell AM; Choi S; Cook J; Conrad P; Dixon B; Dumas J; Ehrlich P; Gane T; Joe T; Johnson J; Jordan J; Kramss R; Liu P; Levy J; Lowe D; McAlexander I; Natero R; Redman AM; Scott W; Seng T; Sibley R; Wang M; Wang Y; Wood J; Zhang Z
Bioorg Med Chem Lett; 2005 Jun; 15(12):3053-7. PubMed ID: 15890515
[TBL] [Abstract][Full Text] [Related]
2. 4,5-Disubstituted cis-pyrrolidinones as inhibitors of type II 17beta-hydroxysteroid dehydrogenase. Part 3. Identification of lead candidate.
Wood J; Bagi CM; Akuche C; Bacchiocchi A; Baryza J; Blue ML; Brennan C; Campbell AM; Choi S; Cook JH; Conrad P; Dixon BR; Ehrlich PP; Gane T; Gunn D; Joe T; Johnson JS; Jordan J; Kramss R; Liu P; Levy J; Lowe DB; McAlexander I; Natero R; Redman AM; Scott WJ; Town C; Wang M; Wang Y; Zhang Z
Bioorg Med Chem Lett; 2006 Sep; 16(18):4965-8. PubMed ID: 16806919
[TBL] [Abstract][Full Text] [Related]
3. Structure-based design, synthesis and in vitro characterization of potent 17beta-hydroxysteroid dehydrogenase type 1 inhibitors based on 2-substitutions of estrone and D-homo-estrone.
Möller G; Deluca D; Gege C; Rosinus A; Kowalik D; Peters O; Droescher P; Elger W; Adamski J; Hillisch A
Bioorg Med Chem Lett; 2009 Dec; 19(23):6740-4. PubMed ID: 19836949
[TBL] [Abstract][Full Text] [Related]
4. Identification of a novel series of tetrahydrodibenzazocines as inhibitors of 17beta-hydroxysteroid dehydrogenase type 3.
Fink BE; Gavai AV; Tokarski JS; Goyal B; Misra R; Xiao HY; Kimball SD; Han WC; Norris D; Spires TE; You D; Gottardis MM; Lorenzi MV; Vite GD
Bioorg Med Chem Lett; 2006 Mar; 16(6):1532-6. PubMed ID: 16386902
[TBL] [Abstract][Full Text] [Related]
5. Inhibitory effects of fluorine-substituted estrogens on the activity of 17beta-hydroxysteroid dehydrogenases.
Deluca D; Möller G; Rosinus A; Elger W; Hillisch A; Adamski J
Mol Cell Endocrinol; 2006 Mar; 248(1-2):218-24. PubMed ID: 16406285
[TBL] [Abstract][Full Text] [Related]
6. Design and synthesis of bisubstrate inhibitors of type 1 17beta-hydroxysteroid dehydrogenase: overview and perspectives.
Fournier D; Poirier D; Mazumdar M; Lin SX
Eur J Med Chem; 2008 Nov; 43(11):2298-306. PubMed ID: 18372081
[TBL] [Abstract][Full Text] [Related]
7. Synthesis and preliminary evaluation of a modified estradiol-core bearing a fused γ-lactone as non-estrogenic inhibitor of 17β-hydroxysteroid dehydrogenase type 1.
Ouellet E; Ayan D; Poirier D
Bioorg Med Chem Lett; 2011 Sep; 21(18):5510-3. PubMed ID: 21782424
[TBL] [Abstract][Full Text] [Related]
8. Substituted 6-phenyl-2-naphthols. Potent and selective nonsteroidal inhibitors of 17beta-hydroxysteroid dehydrogenase type 1 (17beta-HSD1): design, synthesis, biological evaluation, and pharmacokinetics.
Marchais-Oberwinkler S; Kruchten P; Frotscher M; Ziegler E; Neugebauer A; Bhoga U; Bey E; Müller-Vieira U; Messinger J; Thole H; Hartmann RW
J Med Chem; 2008 Aug; 51(15):4685-98. PubMed ID: 18630892
[TBL] [Abstract][Full Text] [Related]
9. Pharmacophore modelling of 17beta-HSD1 enzyme based on active inhibitors and enzyme structure.
Karkola S; Alho-Richmond S; Wahala K
Mol Cell Endocrinol; 2009 Mar; 301(1-2):225-8. PubMed ID: 18822344
[TBL] [Abstract][Full Text] [Related]
10. The derivation of a potential transition state for the reduction reaction catalysed by 17beta-hydroxysteroid dehydrogenase--an approximate representation of its active site for use in drug design and discovery.
Owen CP; Ahmed S
Biochem Biophys Res Commun; 2004 May; 318(1):131-4. PubMed ID: 15110763
[TBL] [Abstract][Full Text] [Related]
11. Synthesis, biochemical evaluation and rationalisation of the inhibitory activity of a series of 4-hydroxyphenyl ketones as potential inhibitors of 17beta-hydroxysteroid dehydrogenase type 3 (17beta-HSD3).
Lota RK; Dhanani S; Owen CP; Ahmed S
Bioorg Med Chem Lett; 2006 Sep; 16(17):4519-22. PubMed ID: 16797984
[TBL] [Abstract][Full Text] [Related]
12. Design, synthesis and biological evaluation of bis(hydroxyphenyl) azoles as potent and selective non-steroidal inhibitors of 17beta-hydroxysteroid dehydrogenase type 1 (17beta-HSD1) for the treatment of estrogen-dependent diseases.
Bey E; Marchais-Oberwinkler S; Kruchten P; Frotscher M; Werth R; Oster A; Algül O; Neugebauer A; Hartmann RW
Bioorg Med Chem; 2008 Jun; 16(12):6423-35. PubMed ID: 18514529
[TBL] [Abstract][Full Text] [Related]
13. Novel and potent 17beta-hydroxysteroid dehydrogenase type 1 inhibitors.
Lawrence HR; Vicker N; Allan GM; Smith A; Mahon MF; Tutill HJ; Purohit A; Reed MJ; Potter BV
J Med Chem; 2005 Apr; 48(8):2759-62. PubMed ID: 15828812
[TBL] [Abstract][Full Text] [Related]
14. Design, synthesis, and biological evaluation of (hydroxyphenyl)naphthalene and -quinoline derivatives: potent and selective nonsteroidal inhibitors of 17beta-hydroxysteroid dehydrogenase type 1 (17beta-HSD1) for the treatment of estrogen-dependent diseases.
Frotscher M; Ziegler E; Marchais-Oberwinkler S; Kruchten P; Neugebauer A; Fetzer L; Scherer C; Müller-Vieira U; Messinger J; Thole H; Hartmann RW
J Med Chem; 2008 Apr; 51(7):2158-69. PubMed ID: 18324762
[TBL] [Abstract][Full Text] [Related]
15. Development of 3-substituted-androsterone derivatives as potent inhibitors of 17β-hydroxysteroid dehydrogenase type 3.
Maltais R; Fournier MA; Poirier D
Bioorg Med Chem; 2011 Aug; 19(15):4652-68. PubMed ID: 21741247
[TBL] [Abstract][Full Text] [Related]
16. Cinnamates and cinnamamides inhibit fungal 17beta-hydroxysteroid dehydrogenase.
Kristan K; Starcević S; Brunskole M; Rizner TL; Gobec S
Mol Cell Endocrinol; 2006 Mar; 248(1-2):239-41. PubMed ID: 16337334
[TBL] [Abstract][Full Text] [Related]
17. Synthesis and biological evaluation of phenyl substituted 1H-1,2,4-triazoles as non-steroidal inhibitors of 17β-hydroxysteroid dehydrogenase type 2.
Al-Soud YA; Marchais-Oberwinkler S; Frotscher M; Hartmann RW
Arch Pharm (Weinheim); 2012 Aug; 345(8):610-21. PubMed ID: 22532378
[TBL] [Abstract][Full Text] [Related]
18. Relative involvement of three 17beta-hydroxysteroid dehydrogenases (types 1, 7 and 12) in the formation of estradiol in various breast cancer cell lines using selective inhibitors.
Laplante Y; Rancourt C; Poirier D
Mol Cell Endocrinol; 2009 Mar; 301(1-2):146-53. PubMed ID: 18812208
[TBL] [Abstract][Full Text] [Related]
19. Coumarins as novel 17beta-hydroxysteroid dehydrogenase type 3 inhibitors for potential treatment of prostate cancer.
Harada K; Kubo H; Tomigahara Y; Nishioka K; Takahashi J; Momose M; Inoue S; Kojima A
Bioorg Med Chem Lett; 2010 Jan; 20(1):272-5. PubMed ID: 19954971
[TBL] [Abstract][Full Text] [Related]
20. Synthesis of 3-spiromorpholinone androsterone derivatives as inhibitors of 17β-hydroxysteroid dehydrogenase type 3.
Djigoué GB; Kenmogne LC; Roy J; Poirier D
Bioorg Med Chem Lett; 2013 Dec; 23(23):6360-2. PubMed ID: 24144853
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]